Dakota Rhys-Jones1,2, Rachel E Climie3,4, Paul A Gill2, Hamdi A Jama1, Geoffrey A Head5,6, Peter R Gibson2, David M Kaye7,8,9, Jane G Muir2, Francine Z Marques10,11. 1. Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash University, 25 Rainforest Walk, Clayton, Victoria, 3800, Australia. 2. Department of Gastroenterology, Central Clinical School, Monash University, Melbourne, Australia. 3. Sports Cardiology, Baker Heart and Diabetes Institute, Melbourne, Australia. 4. Menzies Institute for Medical Research, University of Tasmanian, Hobart, Australia. 5. Neuropharmacology Laboratory, Baker Heart and Diabetes Institute, Melbourne, Australia. 6. Department of Pharmacology, Monash University, Melbourne, Australia. 7. Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, Australia. 8. Central Clinical School, Faculty of Medicine Nursing and Health Sciences, Monash University, Melbourne, Australia. 9. Department of Cardiology, Alfred Hospital, Melbourne, Australia. 10. Hypertension Research Laboratory, School of Biological Sciences, Faculty of Science, Monash University, 25 Rainforest Walk, Clayton, Victoria, 3800, Australia. Francine.marques@monash.edu. 11. Heart Failure Research Group, Baker Heart and Diabetes Institute, Melbourne, Australia. Francine.marques@monash.edu.
Abstract
BACKGROUND: Hypertension is a prevalent chronic disease worldwide that remains poorly controlled. Recent studies support the concept that the gut microbiota is involved in the development of hypertension and that dietary fibre intake may act through the gut microbiota to lower blood pressure (BP). Resistant starch is a type of prebiotic fibre which is metabolised by commensal bacteria in the colon to produce short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate. Previous work in pre-clinical models provides strong evidence that both prebiotic fibre as well as SCFAs (i.e. postbiotics) can prevent the development of hypertension. The aim of this clinical trial is to determine if acetylated and butyrylated modified resistant starch can decrease BP of hypertensive individuals via the modulation of the gut microbiota and release of high levels of SCFAs. METHODS: This is a phase IIa double-blinded, randomised, cross-over, placebo controlled trial. Participants are randomly allocated to receive either a diet containing 40 g/day of the modified resistant starch or placebo (corn starch or regular flour) for 3 weeks on each diet, with a 3-week washout period between the two diets. BP is measured in the office, at home, and using a 24-h ambulatory device. Arterial stiffness is measured using carotid-to-femoral pulse wave velocity. Our primary endpoint is a reduction in ambulatory daytime systolic BP. Secondary endpoints include changes to circulating cytokines, immune markers, and modulation to the gut microbiome. DISCUSSION: The findings of this study will provide the first evidence for the use of a combination of pre- and postbiotics to lower BP in humans. The results are expected at the end of 2021. TRIAL REGISTRATION: Australia and New Zealand Clinical Trial Registry ACTRN12619000916145 . Registered on 1 July 2019.
RCT Entities:
BACKGROUND:Hypertension is a prevalent chronic disease worldwide that remains poorly controlled. Recent studies support the concept that the gut microbiota is involved in the development of hypertension and that dietary fibre intake may act through the gut microbiota to lower blood pressure (BP). Resistantstarch is a type of prebiotic fibre which is metabolised by commensal bacteria in the colon to produce short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate. Previous work in pre-clinical models provides strong evidence that both prebiotic fibre as well as SCFAs (i.e. postbiotics) can prevent the development of hypertension. The aim of this clinical trial is to determine if acetylated and butyrylated modified resistantstarch can decrease BP of hypertensive individuals via the modulation of the gut microbiota and release of high levels of SCFAs. METHODS: This is a phase IIa double-blinded, randomised, cross-over, placebo controlled trial. Participants are randomly allocated to receive either a diet containing 40 g/day of the modified resistantstarch or placebo (corn starch or regular flour) for 3 weeks on each diet, with a 3-week washout period between the two diets. BP is measured in the office, at home, and using a 24-h ambulatory device. Arterial stiffness is measured using carotid-to-femoral pulse wave velocity. Our primary endpoint is a reduction in ambulatory daytime systolic BP. Secondary endpoints include changes to circulating cytokines, immune markers, and modulation to the gut microbiome. DISCUSSION: The findings of this study will provide the first evidence for the use of a combination of pre- and postbiotics to lower BP in humans. The results are expected at the end of 2021. TRIAL REGISTRATION: Australia and New Zealand Clinical Trial Registry ACTRN12619000916145 . Registered on 1 July 2019.
Authors: Seamus P Whelton; Amanda D Hyre; Bonnie Pedersen; Yeonjoo Yi; Paul K Whelton; Jiang He Journal: J Hypertens Date: 2005-03 Impact factor: 4.844
Authors: Francine Z Marques; Erin Nelson; Po-Yin Chu; Duncan Horlock; April Fiedler; Mark Ziemann; Jian K Tan; Sanjaya Kuruppu; Niwanthi W Rajapakse; Assam El-Osta; Charles R Mackay; David M Kaye Journal: Circulation Date: 2016-12-07 Impact factor: 29.690
Authors: Alison N Thorburn; Craig I McKenzie; Sj Shen; Dragana Stanley; Laurence Macia; Linda J Mason; Laura K Roberts; Connie H Y Wong; Raymond Shim; Remy Robert; Nina Chevalier; Jian K Tan; Eliana Mariño; Rob J Moore; Lee Wong; Malcolm J McConville; Dedreia L Tull; Lisa G Wood; Vanessa E Murphy; Joerg Mattes; Peter G Gibson; Charles R Mackay Journal: Nat Commun Date: 2015-06-23 Impact factor: 14.919
Authors: Thomas Beaney; Aletta E Schutte; Maciej Tomaszewski; Cono Ariti; Louise M Burrell; Rafael R Castillo; Fadi J Charchar; Albertino Damasceno; Ruan Kruger; Daniel T Lackland; Peter M Nilsson; Dorairaj Prabhakaran; Agustin J Ramirez; Markus P Schlaich; Jiguang Wang; Michael A Weber; Neil R Poulter Journal: Lancet Glob Health Date: 2018-05-16 Impact factor: 26.763